Understand the source comparison
FOXO4-DRI Senolytic Protocol: Dosing Schedule Comparison
3-Day Standard 5mg/day 15mg 14–21 days First-time users, age <50, preventive senolytic intervention Proven effective in preclinical models; minimal immune activation; ideal for tolerance assessment 5-Day Extended 25mg 21–28 days Age >60, chronic inflammation,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 3-Day Standard
- 5mg/day
- 15mg
- 14–21 days
- First-time users, age <50, preventive senolytic intervention
- Proven effective in preclinical models; minimal immune activation; ideal for tolerance assessment
- 5-Day Extended
- 25mg
- 21–28 days
- Age >60, chronic inflammation, post-radiation therapy
- Higher senescent cell burden requires extended exposure; fatigue and transient inflammation more common
- 3-Day Low-Dose
- 2.5mg/day
- 7.5mg
- 14 days
- Cautious first-time users, autoimmune conditions
- Reduced apoptotic load limits immune flare risk; efficacy unproven in human trials
- 5-Day High-Intensity
- 7.5mg/day
- 37.5mg
- 28+ days
- Research settings only; not recommended outside supervised protocols
- No safety data above 5mg/day; increased cost without confirmed benefit